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Introduction
Reducing sugars can react non-enzymatically with the amino 
groups of proteins to form reversible Schiff bases and then 
Amadori products.1-3 These early glycation products undergo fur-
ther complex reactions such as rearrangement, dehydration and 
condensation to become irreversibly cross-linked, heterogeneous 
fluorescent derivatives termed “advanced glycation end products” 
(AGEs).1-3 The formation and accumulation of AGEs have been 
known to progress during normal aging process and at an accel-
erated rate under hyperglycemic and/or oxidative stress condi-
tions.1-3 There is a growing body of evidence to show that AGEs 
elicit oxidative stress generation and subsequently evoke inflam-
matory and thrombogenic reactions, thus being implicated in 
various devastating disorders such as cardiovascular disease, neu-
rodegenerative disorders, cancers, non-alcoholic steatohepatitis 
and vascular complications in diabetes.4-9
As men grow older, serum testosterone levels decline and 
decreased testosterone level is associated with increased risks of 
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metabolic syndrome, type 2 diabetes, osteoporosis, impaired sex-
ual health and cardiovascular disease.10-14 Further, recently, low 
testosterone level has been shown to predict higher overall and 
cardiovascular-related mortality in middle-aged and older men 
as well.13 Since some interventional studies indicate that testos-
terone substitution may be helpful in preventing the metabolic 
syndrome in aging men,10-14 low testosterone could be a therapeu-
tic target for various cardiometabolic disorders. However, which 
anthropometric and metabolic variables, including AGEs, are 
independently correlated with low testosterone in men is largely 
unknown. In this study, we investigated whether high serum 
level of AGEs is one of the independent determinants of low tes-
tosterone in non-diabetic men.
Results
Backgrounds of the subjects are presented in Table 1. Mean   
serum AGEs and testosterone levels were 9.17 ± 2.69 U/mL 
and 4.84 ± 0.29 ng/mL, respectively. Table 2 shows results www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  263
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with low testosterone levels in non-diabetic men. In order to exclude 
the confounders that could affect the relationship between serum 
levels of AGEs and testosterone, we limited our analysis to non-dia-
betic men without anti-hypertension (HT) drugs, aspirin, statins or 
fibrates because (1) it is well known that serum levels of AGEs are 
significantly elevated in diabetic patients compared to non-diabetic 
subjects by reflecting cumulative hyperglycemic burden,1-4 (2) tes-
tosterone levels are also reported to decrease in diabetic patients,15,16 
and (3) treatments with anti-HT agents, aspirin, statins or fibrates 
could reduce circulating levels of AGEs in humans.17-20
There is accumulating evidence that AGEs play a role in the 
development and progression of cardiovascular diseases in both 
animal models and humans.3,4,21-24 Indeed, an inhibitor of AGE for-
mation, aminoguanidine treatment was reported to decrease accu-
mulation of AGEs and atherosclerotic plaque area in the thoracic 
and abdominal aortas in streptozotocin-induced diabetic apolipo-
protein E-deficient mice.21 Aminoguanidine reduced plaque forma-
tion in the aorta of cholesterol-fed rabbits, and there was a correlation 
between AGE levels and the degree of atheroma in this model.22 
Further, AGEs have been actually detected within atherosclerotic 
of univariate analysis for determinants of testosterone lev-
els. Parameters statistically and significantly related to testos-
terone levels were waist circumference (inversely), diastolic 
blood pressure (BP) (inversely), mean BP (inversely), triglyc-
erides (inversely), high-density lipoprotein-cholesterol (HDL-
cholesterol), fasting plasma glucose (FPG) (inversely), fasting 
insulin (inversely), homeostasis model assessment of insulin 
resistance (HOMA-IR) (inversely), AGEs (inversely) and uric 
acid (inversely). Because these significant parameters were closely 
correlated with each other, multiple stepwise regression analysis 
was performed. Finally, HOMA-IR (inversely, p = 0.005) and 
triglycerides (inversely, p < 0.05) remained significant (Table 3) 
and were independently related to serum testosterone levels (R2 
= 0.168). Further, HOMA-IR index was found to be one of the 
independent determinants of serum levels of AGEs as well.
Discussion
In the present study, we demonstrated for the first time that besides 
metabolic risk factors such as waist circumference, BP, plasma glu-
cose, lipids and uric acids, serum levels of AGEs were correlated 
Table 1. Clinical variables of our subjects
Clinical variables
patients (N) 113
Age (years old) 58.8 ± 8.5
Age (years old) (range) 39–82
Waist circumference (cm) 87.7 ± 8.5
heart rate (beats/minute) 63.4 ± 10.1
systolic Bp (mmhg) 131.3 ± 14.0
Diastolic Bp (mmhg) 83.6 ± 9.5
Mean Bp (mmhg) 99.5 ± 10.5
Total-cholesterol (mg/dL) 210.1 ± 35.7
LDL-cholesterol (mg/dL) 125.8 ± 32.8
hDL-cholesterol (mg/dL) 53.6 ± 12.7
Triglycerides (mg/dL) 125.3 ± 7.5
Fasting plasma glucose (mg/dL) 101.4 ± 6.1
Fasting Insulin (μU/mL) 5.40 ± 0.32
hOMA-IR 1.35 ± 0.08
hbA1c (%) 5.32 ± 0.32
AGes (U/mL) 9.17 ± 2.69
Testosterone (ng/mL) 4.84 ± 0.29
Blood urea nitrogen (mg/dL) 15.2 ± 3.1
Creatinine (mg/dL) 0.82 ± 0.05
Creatinine clearance (mL/min) 94.0 ± 22.7
Uric acid (mg/dL) 6.22 ± 1.14
hs-CRp (mg/L) 0.61 ± 0.04
Current smoker (N) 17
Bp, blood pressure; LDL-cholesterol, low-density lipoprotein-choles-
terol; hDL-cholesterol, high-density lipoprotein-cholesterol; hOMA-IR, 
homeostasis model assessment of insulin resistance; hbA1c, glycosyl-
ated hemoglobin; AGes, advanced glycation end products; hs-CRp, 
high sensitive C-reactive protein; N, number.
Table 2. Univariate analysis for correlates of serum testosterone
Parameters β SE t-value p-value
Age 0.049 0.002 0.518 0.605
Waist circumference -0.349 0.001 -3.926 0.000
heart rate -0.102 0.001 -1.076 0.284
systolic Bp -0.174 0.001 -1.866 0.065
Diastolic Bp -0.214 0.001 -2.313 0.023
Mean Bp -0.206 0.001 -2.220 0.028
Total-cholesterol -0.116 0.000 -1.229 0.222
LDL-cholesterol -0.091 0.000 -0.965 0.337
Triglycerides† -0.326 0.054 -3.627 0.000
hDL-cholesterol 0.252 0.001 2.748 0.007
Fasting plasma glucose† -0.249 0.356 -2.711 0.008
Fasting insulin† -0.359 0.047 -4.048 0.000
hOMA-IR† -0.368 0.044 -4.173 0.000
AGes -0.190 0.005 -2.038 0.044
hbA1c -0.100 0.043 -1.061 0.291
Blood urea nitrogen -0.125 0.004 -1.325 0.188
Creatinine† -0.031 0.208 -0.326 0.745
Creatinine clearance -0.169 0.001 -1.808 0.073
Uric acid -0.258 0.011 -2.810 0.006
hs-CRp† -0.085 0.024 -0.903 0.369
Current smoking -0.048 0.028 -0.505 0.615
Univariate analysis revealed that testosterone levels were associated 
with waist circumference (inversely), diastolic blood pressure (Bp) 
(inversely), mean Bp (inversely), triglycerides (inversely), high-density 
lipoprotein-cholesterol (hDL-cholesterol), fasting plasma glucose 
(inversely), fasting insulin (inversely), homeostasis model assessment 
of insulin resistance (hOMA-IR) (inversely), AGes (inversely) and uric 
acid (inversely). †Log-transformed value was used. LDL-cholesterol, 
low-density lipoprotein-cholesterol; hbA1c, glycosylated hemoglobin; 
hs-CRp, high sensitive C-reactive protein; β, regression coefficients; se, 
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lesions in humans.23 We have previously found that serum levels 
of AGEs are an independent determinant of plasminogen activator 
inhibitor-1, one of the biomarkers of future cardiovascular events, 
in non-diabetic general population.25 In addition, Kilhovd et al. 
reported that serum levels of AGEs could predict total, cardiovas-
cular disease and coronary heart disease mortality in non-diabetic 
subjects, especially women.26 These observations suggest that high 
circulating levels of AGEs may partly explain the increased risk of 
future cardiovascular events in men with low testosterone.
In this study, serum levels of AGEs were associated with low 
testosterone levels in univariate, but not multivariate analy-
sis. Insulin resistance could link the elevation of circulating 
AGE levels to decreased testosterone in our subjects because 
HOMA-IR index, a marker of insulin resistance was found 
to be one of the independent determinants of serum levels of 
testosterone (Table 3) as well as AGEs (p = 0.004). Although 
our study was a cross-sectional one and therefore, did not elu-
cidate the causal relationship among serum levels of AGEs, 
testosterone and insulin resistance, the present study sug-
gests that insulin resistance may be a therapeutic target for 
preventing cardiovascular disease in non-diabetic men with 
low testosterone levels. Longitudinal and/or interventional 
studies are helpful to clarify whether improvement of insu-
lin resistance could decrease circulating levels of AGEs and 
increase testosterone levels and subsequently reduce the risk 
of future cardiovascular events in non-diabetic men.
Research Design and Methods
Subjects. The study involved 113 consecutive male outpa-
tients in Kurume University Hospital with a mean age of 
58.8 ± 8.5 years old. None of the patients received anti-HT 
drugs, aspirin, statins or fibrates. We excluded any patients 
with inflammatory, neoplastic disorders and those who had 
a recent (<3 months) acute coronary syndrome, stroke and 
any acute infection. Patients who received oral hypoglycemic 
agents or insulin injections for the treatment of diabetes melli-
tus (DM) and/or whose FPG was more than 126 mg/dL and/
or whose glycosylated hemoglobin (HbA1c) levels were more 
than 6.5% were also excluded. All participants gave informed 
consent. The Ethical Committee for the Clinical Research of 
Kurume University approved this study.
Data collection. The medical history, use of smoking and 
alcohol were ascertained by a questionnaire. Smoking was clas-
sified as current habitual use or not. Waist circumference was 
measured as an index of central obesity. BP was measured in the 
sitting position using an upright standard sphygmomanometer. 
Vigorous physical activity and smoking were avoided for at least 
30 minutes before BP and resting heart rate measurements.
Blood was drawn from the antecubital vein in the morn-
ing for determinations of lipids (total-cholesterol, low density 
lipoprotein-cholesterol (LDL-cholesterol), triglycerides and 
HDL-cholesterol), plasma glucose, insulin, HbA1c, blood 
urea nitrogen, creatinine, uric acid, high-sensitive C-reactive   
protein (hs-CRP). These blood chemistries were measured 
with standard methods at a commercially available laboratory.   
Table 3. Multiple stepwise regression analysis for correlates of serum 
testosterone
Characteristics β SE Significance
hOMA-IR† -0.278 0.048 0.005
Triglycerides† -0.201 0.058 0.042
Multiple stepwise regression analysis revealed that homeostasis model 
assessment of insulin resistance (hOMA-IR) (inversely, p = 0.005) and 
triglycerides (inversely, p < 0.05) were independently associated with 
serum testosterone levels. †Log-transformed value was used. β, regres-
sion coefficients; se, standard error. R2 = 0.168.
Figure 1. Inverse correlation between serum levels of testosterone and 
AGes. serum levels of AGes were inversely correlated with testosterone 
levels in our subjects. One hundred thirteen consecutive male outpatients 
in Kurume University hospital with a mean age of 58.8 ± 8.5 years old were 
enrolled in the present study. Blood was drawn from the antecubital vein 
in the morning. Measurement of AGes was performed with a competitive 
enzyme-linked immunosorbent assay (eLIsA). In this study, one unit (U) 
corresponds to 1 μg of glyceraldehyde-derived AGe-bovine serum albumin 
standard. serum testosterone level was measured with electro-chemilumi-
nescence immunoassay.
(The Kyodo Igaku Laboratory, Fukuoka, Japan) as described 
previously.27 Measurement of AGEs was performed with a 
competitive enzyme-linked immunosorbent assay (ELISA) as 
described previously.28 In this study, one unit (U) corresponds 
to 1 μg of glyceraldehyde-derived AGE-bovine serum albu-
min standard. Serum testosterone level was measured with 
electro-chemiluminescence immunoassay at SRL Inc., (Tokyo, 
Japan). Insulin resistance was estimated using the HOMA-IR. 
HOMA-IR index was calculated from the values of FPG   
(mg/dL) and fasting insulin (μU/ml) using the following 
formula [(glucose x insulin)/405]. Creatinine clearance was   
calculated with the Cockcroft-Gault equation.29
Statistical methods. Because of skewed distributions, the 
natural logarithmic (ln) transformations were performed for tri-
glycerides, fasting plasma glucose, fasting insulin, HOMA-IR, 
testosterone, serum creatinine and hs-CRP. Univariate analysis 
was performed for determinants of serum testosterone levels. www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  265
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Multiple stepwise regression analysis was performed to deter-
mine independent determinants of testosterone levels. Statistical   
significance was defined as p < 0.05. All statistical analyses 
were performed with the use of the SPSS system (SPSS Inc.,   
Chicago, IL).
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